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Introduction
Modern translational medicine rests upon 
the progressive study of pathways and 
principles from model organisms such 
as yeast, fly, fish, and mouse to clinical 
study in humans. However, as noted by 
the physician William Osler, much of our 
knowledge of human disease is based 
on studies in patients themselves. More 
recently, this approach has extended 
into models of human disease based on 
cultured human cells, where the discov-
ery of the low-density lipoprotein (LDL) 
receptor pathway in skin fibroblasts from 
patients with familial hypercholester-
olemia ultimately led to one of the biggest 
advances in clinical cardiovascular med-
icine. However, many of the most impor-
tant and puzzling human cardiovascular 
diseases cannot be adequately studied 
because specific human cardiovascular 
cell types—such as cardiomyocytes, 
endothelial cells (ECs), and vascular 
smooth muscle cells (VSMCs)—cannot 
be obtained. Although animal models 
will continue to be invaluable, there is 
a huge advantage to studying specific 
cardiovascular cell types from patients 
with specific forms of heart disease. The 
discovery of multipotent cardiovascular 
progenitor cells not only in mammalian 
embryos and postnatal (adult) heart but 
also as an intermediate stage during dif-
ferentiation of embryonic stem (ES) cells 
is an important step toward reaching 
this goal.
Sophisticated genetic approaches in 
model organisms provide unique oppor-
tunities for determining the embryonic 
origins and fates of cardiac progenitor 
cells. This has taught us much about 
their developmental potency and abil-
ity to differentiate 
into the major func-
tional cell lineages 
of the heart: car-
diomyocytes, ECs, 
VSMCs, and car-
diac fibroblasts. The 
existence of cardiac 
progenitor cells in adult heart is of par-
ticular interest because the heart was 
long considered to be without a resident 
stem cell population. Here, we discuss 
cardiac progenitor cells from fetal and 
adult heart and from in vitro differenti-
ated pluripotent stem cells because (1) 
alterations in the pool of cardiac progen-
itors during development may be caus-
ally related to congenital heart defects; 
(2) expansion of cardiac progenitors in 
culture is potentially the most efficient 
way of producing large numbers of car-
diovascular cells for future cell therapy 
and drug screens; (3) gene targeting in 
human ES cells is a promising approach 
for generating cardiac progenitors and 
their derivatives with specific, clinically 
relevant gene mutations for elucidating 
disease mechanisms. In this context, the 
recent reports on direct reprogramming 
of human skin fibroblasts to induced 
pluripotent stem (iPS) cells with an ES 
cell-like phenotype are particularly excit-
ing because if derived from patients 
carrying gene mutations affecting the 
cardiovascular system, it should be 
possible to obtain cardiac progenitors 
with the same mutations (see Review by 
C.E. Murry and G. Keller and Review by 
R. Jaenisch and R. Young in this issue 
of Cell). This may allow pathogenesis 
to be followed at the cellular level “in a 
dish” and should enable molecular and 
genetic screens to find drugs to halt or 
reverse the disease phenotype.
Cardiac Progenitors in Mouse Fetal 
and Adult Heart
The origin of heart-forming cells and their 
roles in organ development have fasci-
nated biologists for over a century. Pio-
neering work in lower vertebrate species 
such as frog and chick have laid the blue-
print for modern cardiac developmental 
biology by identifying the mesoderm as 
the germ layer responsible for mammalian 
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“He who studies medicine without books sails 
an uncharted sea, but he who studies medicine 
without patients does not go to sea at all.”
 
—William Osler (1849–1919)
Figure 1. Origins of Cardiac Progenitor Cells in the Developing Heart
Cells from the developing mesoderm of the mouse embryo are marked by the expression of Brachyury T at E6.5 of embryonic development (yellow). As they 
transition into precardiac mesoderm, they start to express Mesp1 (pink) and Flk-1 (purple). As these cardiac precursor cells reach the anterior and lateral plate 
mesoderm, they commit irreversibly to become cardiac progenitor cells by expressing Nkx2.5 (green) or Isl-1 (blue) at E7.0. Midline fusion of lateral plate me-
soderm and differentiation of these two cell populations results in the formation of Nkx2.5+ embryonic heart tube (green; E8.25 and E8.5) and Isl-1+ pharyngeal 
mesoderm (blue; E8.25 and E8.5). Some of the pharyngeal mesoderm cells also express Nkx2.5 (not shown). As the heart progresses through embryonic and 
postnatal development, it acquires a four-chambered identity and is functionally integrated with the systemic vasculature. Within the adult heart reside several 
different populations of cardiac stem cells including side population (SP) cells and cells that express c-Kit or Sca-1. (Ao, aorta; SVC, superior vena cava; PA, 
pulmonary artery; RV, right ventricle).cardiogenesis (Rawles, 1943). Precursors 
for heart-forming cells in the vertebrate 
mesoderm transition from expressing 
Brachyury T, a T-box transcription fac-
tor, to expressing mesoderm posterior 1 
(Mesp1) when they enter the precardiac 
mesoderm stage of development (Sollo-
way and Harvey, 2003) (Figure 1). Mesp1+ 
cells encompass all cardiac progeni-
tor cells and their expression of Mesp1 
is turned off as they migrate away from 
the primitive streak. During their migra-
tion, cardiac precursor cells expand rap-
idly to form the anterior and lateral plate 
mesoderm where they eventually gener-
ate a crescent-shaped structure called 
the cardiac crescent (Figure 1). Mesp1+ 
cells have not yet committed to the car-
diogenic fate as some also give rise to 
derivatives of the paraxial mesoderm 
and skeletal muscle of the head and 
neck (Saga et al., 1999). It is at the car-
diac crescent stage that heart precursor 
cells commit irreversibly to the cardiac 
lineage and become cardiac progeni-
tor cells expressing key developmental 
transcription factors such as Nkx2.5 and 
Isl-1. Progressive restriction of develop-
mental potency is believed to take place 
during this time given that cells express-
ing Mesp1 contribute broadly to all four 
main cell types in the heart. Cardiogenic 
Isl-1+ or Nkx2.5+ cells contribute pri-538 Cell 132, February 22, 2008 ©2008 Elsemarily to cardiomyocytes and VSMCs 
with limited contribution to ECs (Saga 
et al., 2000; Sun et al., 2007; Moses et 
al., 2001; Stanley et al., 2002). This step-
wise commitment of cardiac progenitor 
cells toward their differentiated progeny 
has allowed the use of genetic marking 
techniques, such as Cre-Lox, to assign 
a precursor/descendant relationship to 
cells within the developing heart. With 
this approach it has been shown that 
cells in the first heart field (marked by 
the expression of Tbx5 or the first wave 
of Nkx2.5) give rise to the left ventricle 
and portions of the right and left atrium, 
whereas cells in the second heart field 
(marked by the expression of Isl-1 or the 
second wave of Nkx2.5) contribute to 
the right ventricle, the outflow tract, and 
portions of both atria (Cai et al., 2003). 
Interestingly, using retrospective clonal 
analysis, a powerful genetic approach 
to tag single cells during early develop-
ment, Meilhac et al. (2004) have dem-
onstrated a common embryonic origin 
for some cells in the first and second 
heart fields (reviewed in Buckingham et 
al., 2005). Indeed, given that Cre-Lox-
based approaches are dependent on 
the expression domain of key cardiac 
transcription factors, which may extend 
beyond a single heart field, it is essential 
that clonal analysis be performed when vier Inc.multipotentiality is being ascribed to 
new progenitor cell populations that are 
identified based on the expression of a 
specific gene.
By combining transgenic expression 
of fluorescent proteins and fluorescence-
activated cell sorting (FACS), the biologi-
cal phenotype and molecular behavior of 
these embryonic cardiac progenitor cells 
have recently been elucidated (Wu et al., 
2006; Moretti et al., 2006; Kattman et al., 
2006). Depending on the markers used 
and the developmental stage examined, 
embryonic cardiac progenitor cells may 
be bi or tri-potent and may differenti-
ate spontaneously into one or more of 
the three cell lineages: cardiomyocytes, 
VSMCs, and ECs. Collectively, these 
studies provide a shift in our understand-
ing of mammalian cardiogenesis, that is, 
multipotent progenitor cells contribute 
to the formation of a functional heart 
by making lineage choice decisions at 
a single-cell level. This is similar to the 
development of other stem cell-medi-
ated systems such as blood, skin, and 
intestine.
The existence of these embryonic 
multipotent cardiac progenitor cells 
has prompted a search for their pres-
ence in the postnatal heart. Laugwitz 
et al. (2005) have identified a neonatal 
Isl-1+ cardiac progenitor cell population 
with the capacity for differentiation into 
fully mature cardiomyocytes. It remains 
to be seen whether these multipotent 
embryonic cardiac progenitor cells pos-
sess the capability for self-renewal and 
asymmetric division to meet the strict 
definition of cardiac stem cells. If so, 
these embryonic cardiac stem cells 
may be the developmental precursor to 
adult cardiac stem cells that have been 
recently described (see below), although 
they may not necessarily have the same 
molecular identity.
The notion that the adult mammalian 
heart may harbor stem cells with replica-
tive and regenerative capacity was sug-
gested initially by a study in patients with 
myocardial infarction (Beltrami et al., 
2001). This study showed an increased 
number of immature cardiomyocytes 
with the capacity for mitotic division in 
the infarct border zone that may have 
originated from a circulating or endog-
enous stem cell pool. The same investi-
gators subsequently isolated a lineage-
negative, c-Kit-positive (Lin−, Kit +) cell 
population from adult mice that was 
reportedly clonogenic, self-renewing, 
and capable of differentiating into car-
diomyocytes, VSMCs, and ECs (Beltrami 
et al., 2003). Shortly thereafter, two other 
groups reported the isolation of adult 
cardiac stem cells based on the expres-
sion of either Sca1 or the ATP-binding 
cassette transporter (ABCG2; these cells 
are also known as side population or SP 
cells because of their ability to pump out 
Hoechst and rhodamine dyes) (Oh et al., 
2003; Martin et al., 2004). These three 
populations of adult cardiac progenitor 
cells (c-Kit +, Sca1+, or SP) are pheno-
typically different and show differential 
expression of surface markers (Murry et 
al., 2006; Evans et al., 2007; Laugwitz et 
al., 2005; Parmacek and Epstein, 2005; 
Table S1). These three cell populations 
represent 1%–2% of the total cell num-
ber in the heart, enter the cell cycle when 
growth of the heart is attenuated, prolif-
erate in culture, and form cells express-
ing cardiomyogenic markers (Hierlihy et 
al., 2002; Pfister et al., 2005). The exact 
lineage relationships between these 
adult cardiac progenitor cell populations 
and embryonic cardiac progenitor cells 
is unknown. Analysis of cells expressing 
c-Kit following transplantation of GFP-
labeled bone marrow-derived mono-nuclear cells into sublethally irradiated 
wild-type adult mice showed that c-Kit+ 
cells in the adult heart are derived mostly 
from the transplanted marrow cells 
(Fazel et al., 2006); those not derived 
from transplanted cells but present in 
the host could be the recently discov-
ered c-Kit+ population found in multiple 
organs including heart (Massberg et al., 
2007). These c-Kit+ cells exit the bone 
marrow in minute numbers and reside 
in peripheral tissues where they scout 
for pathogenic molecules and promote 
a local innate immune response. Never-
theless, injection of adult cardiac stem 
cells directly into infarcted mouse myo-
cardium has been reported to provide 
short-term improvement in heart func-
tion (Beltrami et al., 2003; Oh et al., 2003; 
Messina et al., 2004) although evidence 
of cardiomyocyte differentiation is lim-
ited. Paracrine factors or angiogenesis 
may have been partly responsible for 
the reported benefit. Indeed, clinical tri-
als using bone marrow-derived stem cell 
infusions into patients with myocardial 
infarction also suggest that paracrine 
factors may be responsible for the tran-
sient improvement in cardiac function in 
humans (Meyer et al., 2006).
Cardiac Progenitors in Human Fetal 
and Adult Heart
The presence of endogenous cardiac 
progenitors in the mouse fetal and adult 
heart prompted studies into whether 
similar populations exist in the human 
heart. An initial study described the iso-
lation of a heterogeneous population of 
cells from human atrial and ventricular 
biopsies that form clonal multicellular 
clusters in suspension culture called 
“cardiospheres” (Messina et al., 2004). 
These cardiospheres consist of c-Kit+ 
cells at the core and cells expressing 
cardiac and EC markers at the periphery. 
Cardiomyocytes derived from cardio-
spheres will only contract if cocultured 
with neonatal rat cardiomyocytes. More 
recently, cardiosphere-derived cells were 
isolated with improved efficiencies from 
endomyocardial right ventricular biopsies 
from adult patients (Smith et al., 2007). 
Concurrently, several studies identified 
an endogenous cardiac c-Kit+ cell popu-
lation from patients with aortic stenosis 
or post-heart transplantation (Quaini et 
al., 2002; Urbanek et al., 2003) (Table Cell 132,S1). These cells were MDR1+ (multidrug 
resistance gene 1) but did not express 
hematopoietic or endothelial progenitor 
cell markers. When isolated by FACS, 
human cardiac c-Kit+ cells were reported 
to give rise to cardiomyocytes, VSMCs, 
and ECs in vitro and following transplan-
tation into immunodeficient mice (Bearzi 
et al., 2007). Interestingly, some of the 
c-Kit+ cells identified as a minute popula-
tion in human heart were recently shown 
to be mast cells, based on the presence 
of the enzyme tryptase and absence of 
Nkx2.5 or Isl-1 expression, independent 
of whether they were present in atrium 
or ventricle or whether they were sorted 
by FACS and then cultured (Pouly et al., 
2008). Although not all c-Kit+ cells may 
have been accounted for, these results 
raise a cautionary note with respect to 
speculation on their future clinical appli-
cations.
Different cell populations with the 
capacity to proliferate and form cardio-
myocytes in adherent cell culture have 
been isolated independently from both 
human adult heart (biopsies) and fetal 
heart on the basis of their ability to bind 
to an anti-mouse Sca-1 antibody. Their 
authenticity as cardiac progenitors, how-
ever, has been debated because Sca-1 
is not a determinant on human cells and 
5-azacytidine is required to induce differ-
entiation. 5-azacytidine induces genom-
ewide demethylation and its effects are 
nonspecific. Nevertheless, the differen-
tiated progeny of these progenitors do 
have properties of bona fide cardiomyo-
cytes (such as sarcomeric proteins orga-
nized into sarcomeres and spontaneous 
action potentials). The differentiation 
of these cells may depend on another 
important population of cells in the heart 
termed cardiac fibroblasts, which gen-
erate extracellular matrix and provide 
the heart with elasticity and mechani-
cal strength. Cardiac fibroblasts lack 
markers for cardiomyocytes, ECs, and 
nerve cells but express discoidin domain 
receptor 2 and Thy-1 (Hudon-David et al., 
2007). They are derivatives of the portion 
of the epicardium that underwent epithe-
lial-mesenchymal transformation during 
cardiogenesis. These cells also give rise 
to coronary VSMCs and ECs. Epicardial 
cells regulate the formation of the com-
pact myocardium, coronary vasculature, 
and Purkinje fiber network as well as the  February 22, 2008 ©2008 Elsevier Inc. 539
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fibrous structures of the heart 
(Winter and Gittenberger-de 
Groot, 2007). If adult car-
diac “fibroblasts” recapitu-
late the essential properties 
of epicardium-derived cells 
in a diseased myocardium, it 
would support the hypothesis 
that the epicardium may also 
be the origin of progenitors in 
the adult heart (Lepilina et al., 
2006). This would be compat-
ible with the fact that Isl-1+ 
cells are detectable in human 
neonates (as a “carry over” of 
second heart field progeni-
tors) but are absent in adult 
hearts (Laugwitz et al., 2005; 
Qyang et al., 2007), suggest-
ing that cardiac progenitors 
identified during later stages 
of life may arise de novo 
from the epicardium. Studies 
aimed at defining the precise 
lineage relationship between 
Isl-1+ second heart field cells 
and progenitor cells for the 
proepicardial organ will help 
to clarify the intrinsic differ-
ences between these two cell 
populations.
Cardiac Progenitors from 
ES Cells and iPS Cells
Pluripotent ES cells have been 
instrumental in identifying and 
characterizing cell populations 
of the early stages of develop-
ment and lineage commitment, 
which are difficult to study in 
the embryo. They represent a 
renewable source of multiple 
progenitors including those of 
the cardiovascular and heman-
gioblast lineages. In humans, 
ES cells are derived from early 
embryos discarded after in 
vitro fertilization. They can be induced by 
a variety of methods to undergo stepwise 
differentiation to mesoderm (expressing 
Brachyury T) and then to cardiac pro-
genitors (expressing GATA-4, Nkx2.5, 
and Isl-1). Finally, they differentiate into 
cardiomyocytes (expressing MHC, cTNI, 
α-actinin, and other proteins of the con-
tractile machinery; Beqqali et al., 2006; 
Kehat et al., 2001; Passier et al., 2005), 
ECs (Levenberg et al., 2002; Ferreira et al., 
2007), and VSMCs. Whether the cardio-
myocytes or ECs derived from mouse or 
human ES cells represent derivatives of the 
first or second heart fields or the proepi-
cardial organ remains to be established, 
but approaches using genetic markers 
or physical selection of subpopulations 
using cell-surface antibodies as in mouse 
ES cells (Kouskoff et al., 2005; Kattman et 
al., 2006) should provide an answer. ECs 
can also develop independently of cardiac 
progenitors via the hemangio-
blast (Kennedy et al., 2007; Lu 
et al., 2007). It will be of interest 
to compare these cells directly 
with those derived from car-
diac progenitors.
Cardiovascular cells derived 
from ES cell sources are highly 
desirable for several reasons: 
they can carry natural or 
induced gene mutations for 
functional analysis and drug 
screens, they can in principle 
be scaled up reproducibly for 
cell-based therapies, and they 
can be genetically marked 
for cell selection (Figure 2). 
However, the best targets for 
expansion in culture are prob-
ably not the undifferentiated 
stem cells but rather com-
mitted progenitors derived 
from them as they are most 
likely to yield homogeneous 
populations of differentiated 
cells without contaminating 
(potentially tumorigenic) ES 
cells. Being able to identify, 
select, and expand these pro-
genitors is then of immediate 
importance. Ectopic reporter 
gene expression or, even bet-
ter, gene targeting has already 
been successful in selecting 
cells at different stages and 
with different identities in the 
cardiovascular differentiation 
pathway of mouse ES cells 
(Meyer et al., 2000; Kouskoff 
et al., 2005; Wu et al., 2006; 
Moretti et al., 2006). However, 
gene transfer has been chal-
lenging in human ES cells 
so that only now are the first 
reporter lines for human car-
diovascular lineages emerging 
(Anderson et al., 2007; Huber 
et al., 2007). Alternatively, an option cir-
cumventing the need for genetic modifi-
cation would be selection on the basis of 
known cell-surface antigens, which has 
been used successfully with mouse ES 
cells to enrich for cell populations with 
cardiovascular differentiation potential 
(Kattman et al., 2006; Kouskoff et al., 
2005). Even better would be sets of anti-
bodies able to select cardiac progeni-
tors at different stages of development. 
Figure 2. Therapeutic Implications of Cardiac Progenitor Cells
Progenitor cells have been described in fetal and adult heart in multiple spe-
cies including humans. They also form as an intermediate in the differentiation 
of embryonic stem (ES) cells giving rise to cardiomyocytes, smooth muscle 
cells, and endothelial cells. Cardiac progenitors may be uni-, bi-, or tri- po-
tent, depending on their molecular signatures although this relationship is still 
under investigation. Cardiomyocytes are morphologically readily identifiable 
by α-actinin staining (red, left panel) of sarcomeric structures, endothelial 
cells by expression of surface markers such as PE-CAM (green, middle panel 
and inset), and vascular smooth muscle cells that surround blood vessels 
by smooth muscle actin (sma; red, right panel and inset). Cells expressing 
Nkx2.5 in the fetal mouse heart are indicated by green fluorescent protein 
(GFP) in a transgenic Nkx2.5-GFP mouse. Photos courtesy of C. Mummery 
(blastocyst; cardiomyocyte); F. Lebrin, D. Ward, and L. Tertoolen (endothelial 
cell and vascular smooth muscle cell); Sean Wu (fetal heart).
However, with the exception of ECs, cell 
type-specific surface antibodies do not 
yet exist for most lineages.
Most human ES cell derivatives 
acquire only a fetal phenotype and do 
not fully mature unless placed in an 
environment resembling normal tissue. 
Cardiomyocytes derived from human ES 
cells are also generally immature with 
radially organized sarcomeres and low 
action potentials (Mummery et al., 2003). 
Although this may be beneficial for future 
cell-based therapies as only fetal, not 
adult, cardiomyocytes survive trans-
plantation in the heart (Koh et al., 1995; 
Klug et al., 1996), many other challenges 
presently preclude therapeutic applica-
tion. Aside from perceived tumorigenic 
risk, such challenges include stable 
integration of transplanted cells into the 
host myocardium, control of fibrosis and 
abrogation of immune attack of the cell 
graft, and a sustained contribution to 
contractile activity that is lost after myo-
cardial infarction. This is independent 
of the particular source of cardiac pro-
genitors from which the fully differenti-
ated cardiomyocytes are derived. Sev-
eral studies have described successful 
transplantation and long-term survival of 
grafts from contracting (beating) human 
ES cell cultures containing cardiomyo-
cytes (Caspi et al., 2007; Laflamme et al., 
2007; van Laake et al., 2007); however, 
none have reported long-term functional 
improvements and the grafts may form 
isolated syncytia rather than becoming 
truly integrated into existing myocar-
dium. In contrast to cell therapies, drug 
screens or physiological analysis of dis-
ease properties in vitro will most likely 
require an adult cardiomyocyte phe-
notype. This will require ways to drive 
fetal and adult cardiac progenitors and 
human ES cells toward cardiomyocyte 
maturation, perhaps using cardiac tissue 
constructs that allow cells to contract 
in unison and exert positive mechanical 
forces (Zimmermann et al., 2006; Fein-
berg et al., 2007).
Although human ES cells represent 
an exciting platform for technology 
development, gene targeting of these 
cells and creation of disease models in 
culture are challenging. The alternative 
strategy—somatic cell nuclear transfer 
(using adult somatic cells from patients 
with specific diseases) and then deriv-ing the ES cell lines from cloned 
embryos—seems feasible given recent 
successes in nonhuman primates 
(Byrne et al., 2007); however, low effi-
ciency and the scarcity of human eggs 
are severely rate limiting. Both of these 
approaches have associated ethical 
issues. Extremely exciting, however, is 
the recent demonstration that human 
skin fibroblasts can be converted to 
human ES cell-like cells (Takahashi et 
al., 2007; Yu et al., 2007). These iPS 
cells express markers of human ES 
cells and are capable of multilineage 
differentiation in vitro and form tera-
tomas in vivo, characteristic of pluri-
potent stem cells. The requirement for 
virally inserting three or four genes into 
the adult human somatic cells will likely 
preclude cell therapy applications in 
the immediate future. Also, epigenetic 
differences between iPS cells and 
human ES cells suggest that iPS cells 
may not behave identically to human ES 
cells. However, iPS cells may be par-
ticularly useful for bedside-to-bench 
research (that is, reverse translational 
medicine) by allowing the creation of 
accurate models of genetic disease in 
the culture dish. For example, patients 
with either Long QT Syndrome (where 
the electrical action potential dura-
tion during heart muscle contraction is 
prolonged leading to sudden cardiac 
death) or hypertrophic cardiomyopathy 
(where excess growth of heart muscle 
cells induces impaired heart function 
and increases risks for lethal arrythmia) 
could donate their skin cells to be con-
verted into iPS cells. The resulting iPS 
cells could then be differentiated into 
cardiac progenitors and their deriva-
tives that would bear the same genetic 
mutations as the patients. Using the 
techniques developed for human ES 
cells, basic electrophysiology, genome 
and proteome comparisons, and res-
cue experiments could then be carried 
out to understand the mechanisms of 
disease pathogenesis and to develop 
strategies for ameliorating its manifes-
tation or for developing cures. Clearly, 
iPS cells will not preclude the need to 
continue research on human ES cells, 
and undoubtedly a decade of informa-
tion derived from human ES cells will 
further the significance and applicabil-
ity of iPS cells.Cell 132Cardiac Progenitors and  
Implications for Therapy
Stem cell and progenitor cell-based 
therapies hold tremendous promise for 
restoring cardiac functions in a variety of 
degenerative diseases including ischemic 
cardiomyopathy and conduction system 
diseases (such as sinus node dysfunc-
tion and atrial-ventricular block) as well as 
congenital heart diseases (such as atrial 
or ventricular septal defect where the wall 
between atrial or ventricular chambers is 
incompletely formed). The prospect for 
achieving a cure for ischemic cardiomyo-
pathy with stem cells was felt to be so 
great that clinical trials were undertaken 
using autologous adult stem cells from a 
variety of noncardiac sources (Janssens 
et al., 2006; Assmus et al., 2006; Lunde et 
al., 2006; Schächinger et al., 2006). These 
trials set out to demonstrate improved 
cardiac function via neocardiomyogen-
esis with developmental plasticity as the 
scientific principle underpinning the strat-
egy. It is clear now that noncardiac stem 
cells are unlikely to result in the formation 
of sufficient numbers of new cardiomyo-
cytes to affect heart function. Neverthe-
less, regardless of the cell type injected, 
there appears to be a small but statistically 
significant improvement in heart function. 
The clinical significance of this improve-
ment is being debated and there is no 
evidence thus far of reduction in important 
end-points such as improved survival or 
reduced heart failure-related hospitaliza-
tion. The new hypothesis that paracrine 
action of the transplanted cells or induced 
vasculogenesis may be responsible for 
the observed functional improvement now 
awaits further confirmation (reviewed in 
Laflamme et al., 2007). Will the experiences 
from this initial foray into stem cell-based 
therapy predict the outcome of future trials 
using cardiac stem or progenitor cells from 
adult heart or derived from ES cells or iPS 
cells? Regardless of whether endogenous 
or ES/iPS cell-derived cardiac progenitor 
cells ever make their way into transplant-
able cell sources for therapy, it is clear 
that these cells will continue to shed light 
on fundamental mechanisms important 
for heart formation and regeneration. By 
defining the molecular identity of multi-
potent cardiac progenitor cells and the 
means by which they can make lineage 
choice decisions to become either cardio-
myocytes, VSMCs, ECs, or mesenchyme , February 22, 2008 ©2008 Elsevier Inc. 541
fibroblasts, we place ourselves at the helm 
in determining the most promising means 
for cardiac therapy. This may require the 
creation of an engineered tissue graft 
(containing cardiomyocytes, with ECs and 
VSMCs organized into vasculature), the 
identification of new pathways to generate 
drug targets, or even the generation of a 
bioartificial heart. In any case, accessibility 
of cardiac progenitors represents a signifi-
cant advantage over differentiated cells or 
undifferentiated pluripotent stem cells to 
achieve large-scale production of tumor-
free cardiac cells for clinical and transla-
tional applications.
Perspectives
Recent advances in our understanding 
of developmental and stem cell biology 
of the cardiovascular system are bringing 
us closer to making mammalian cardiac 
regeneration a clinical reality. This calls for 
a new experimental paradigm of bedside-
to-bench research where the initial funda-
mental observations are made in human 
patients and then are followed up by more 
rigorous mechanistic analyses in model 
organisms. This strategy may be applica-
ble to a number of diseases for which there 
are few valid animal model systems, such 
as complex chromosomal disorders, poly-
genic disorders where common genetic 
variants confer susceptibility or resistance 
to disease, and well-characterized genetic 
disorders that are not adequately reca-
pitulated in animal models. In addition, 
drug discovery, cardiotoxicity screening of 
new drugs, and identification and valida-
tion of therapeutic targets should soon be 
conducted directly on human cardiovas-
cular cells derived directly from patients. 
Cardiovascular stem cell biology may well 
herald a new era of reverse translational 
medicine.
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